Scientists say they have coaxed uncommitted mouse embryonic stem cells to grow into sperm cells in the laboratory.
Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC
In total, the phase 1/2 PRESERVE-006 trial is expected to enroll 144 patients across 20 clinical trial sites in the US.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Study shows potential savings on urology drugs with Mark Cuban Drug Company
For 90-tablet prescriptions, the greatest costs saving were observed for solifenacin and oxybutynin, used for overactive bladder, and tadalafil, used for erectile dysfunction
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
Neoadjuvant chemotherapy found safe, efficacious in penile cancer
Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.
UroActive System shows promise in first female patient with SUI
Overall, the patient met the study’s primary outcome measures of successful device activation and the rate of explants and revisions at 6 months.
2 Commerce Drive Cranbury, NJ 08512